DNER and hematologic disorder: CPI-0610, a selective BET inhibitor, has entered the clinical trial for hematologic malignancies such as myelofibrosis and lymphoma to evaluate its safety, tolerability, and potential efficacy as monotherapy and combination therapy (NCT01949883).